IDEAYA Biosciences (IDYA) Non-Current Assets (2018 - 2026)
IDEAYA Biosciences (IDYA) posted Non-Current Assets of $334.2 million for Q1 2026, down 24.48% sequentially from $442.6 million in Q4 2025, and down 14.9% YoY from $392.8 million in Q1 2025.
IDEAYA Biosciences (IDYA) Non-Current Assets (2018 - 2026) Analysis & Trends
IDEAYA Biosciences has reported Non-Current Assets for 9 years, with the latest figure at $334.2 million in Q1 2026.
- Quarterly Non-Current Assets fell 14.9% year-over-year to $334.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 billion (up 8.58% YoY) and the FY2025 annual result came in at $442.6 million, up 1.89% from the prior year.
- Non-Current Assets declined to $334.2 million in Q1 2026 per IDYA's latest filing, from $442.6 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $442.6 million in Q4 2025 and troughed at $17.5 million in Q3 2022.
- A 5-year average of $210.6 million and a median of $252.2 million in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2024: Non-Current Assets plunged 86.61% in 2022, then soared 1113.07% in 2024.
- Over 5 years, Non-Current Assets stood at $17.5 million in 2022, then soared by 566.19% to $116.7 million in 2023, then surged by 272.27% to $434.4 million in 2024, then climbed by 1.89% to $442.6 million in 2025, then declined by 24.48% to $334.2 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $334.2 million, $442.6 million, and $382.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | IDEAYA Biosciences | 3.50 Bn | 2.67 Bn | - | 445.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 445.67 Mn |
| Mar 31, 2026 | 334.24 Mn |
| Dec 31, 2025 | 442.60 Mn |
| Sep 30, 2025 | 382.48 Mn |
| Jun 30, 2025 | 355.67 Mn |
| Mar 31, 2025 | 392.77 Mn |
| Dec 31, 2024 | 434.38 Mn |
| Sep 30, 2024 | 307.66 Mn |
| Jun 30, 2024 | 260.48 Mn |
| Mar 31, 2024 | 252.17 Mn |
| Dec 31, 2023 | 116.68 Mn |
| Sep 30, 2023 | 50.76 Mn |
| Jun 30, 2023 | 25.77 Mn |
| Mar 31, 2023 | 20.79 Mn |
| Dec 31, 2022 | 17.52 Mn |
| Sep 30, 2022 | 17.47 Mn |
| Jun 30, 2022 | 65.82 Mn |
| Mar 31, 2022 | 102.82 Mn |
| Dec 31, 2021 | 130.35 Mn |
| Sep 30, 2021 | 130.48 Mn |